# Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America

> **NCT00546078** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 116 (actual)

## Conditions studied

- Infections, Papillomavirus

## Interventions

- **BIOLOGICAL:** Cervarix™

## Key facts

- **NCT ID:** NCT00546078
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01-14
- **Primary completion:** 2008-12-22
- **Final completion:** 2009-12-01
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2018-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00546078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00546078, "Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00546078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*